Medidata Solutions and Chiltern Announce ASPire to Win Partnership

Medidata Solutions, a global provider of electronic clinical data
capture (EDC), management and reporting solutions, today announced
that Chiltern Ltd, a full service contract research organization
(CRO), has signed as a partner through Medidata's ASPire to Win(TM)
Program. With this partnership, Medidata will provide the tools and
training that will enable Chiltern to implement Medidata Rave(R) to
manage the company's global Phase I-IV clinical development and late
phase programs.

As an early adopter of EDC, Chiltern provides necessary technical
project management, team training and site level training in support
of EDC implementation and adoption. Chiltern's dedicated EDC services
to sponsors range from pilot programs to support of enterprise-level
implementation. The company is looking to expand its service
offerings, and after a review of the leading EDC vendors, Chiltern
selected Medidata Rave.

"We selected Medidata Rave since it is the leading EDC solution
for ease of use and implementation. Rave has received an outstanding
response from our users," said Glenn Kerkhof, Chiltern's Chief
Executive Officer. "We felt Medidata was an ideal partner because of
our common commitment to quality and compliance to regulatory
expectations, globally."

Medidata's ASPire to Win Program is a non-exclusive application
service provider (ASP) partnership and business model. The program
will allow Chiltern to meet sponsor demand for Medidata Rave and offer
the platform in-house. As a result, Chiltern will be able to create
new services revenue around the implementation of this
industry-leading technology.

Chiltern will leverage Medidata's ASPire to Win Program to build
on the company's established presence as an EDC provider. The Rave
certification will allow Chiltern's EDC Solutions Group to continue to
expand their offerings for sponsors. This group currently provides
advice and support for all EDC trials within Chiltern and assists with
site and sponsor training as needed.

"Along with a progressive view of clinical technology, Chiltern
has an impressive client base and a broad global reach," said Tarek
Sherif, CEO of Medidata Solutions. "Through our ASPire to Win Program,
Chiltern will be able to quickly realize the benefits and ROI that
Medidata Rave brings and build upon its existing position in the CRO
market."

About Chiltern

Established in 1982, Chiltern is a leading global contract
research organization with extensive experience of running and
staffing international Phase I to Phase IV clinical trials across a
broad therapeutic range for a wide variety of clients. Chiltern
employs more than 1000 people with 18 offices across the United
States, Europe and India. Chiltern provides development services
including Early Phase, Global Clinical Development, Late Phase,
Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

About Medidata Solutions Worldwide

Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.